Drugs / LBL-047
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07323173 | Dec 2025 → Dec 2027 expected | systemic lupus erythematosus | Nanjing Leads Biolabs Co.,Ltd | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-23 | Dianthus Therapeutics | Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) dianthustx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LBL-047 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07323173 ↗ |
| Route | Subcutaneous | “Single subcutaneous injection” NCT07323173 ↗ |